Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acapatamab in metastatic castration-resistant prostate cancer
NCT03792841Phase 1Terminated
- Sponsor
- Amgen
- Start
- Feb 2019
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 10
01
Overview
Phase 1, open-label trial of acapatamab in metastatic castration-resistant prostate cancer (mCRPC) (7 arms), sponsored by Amgen. Primary endpoints: Dose-Limiting Toxicity at 3 years, Treatment-Emergent Adverse Events at 3 years and 4 more. Started Feb 2019; status: terminated.
02
Drugs
acapatamab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03792841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03792841.